Company Overview and News

0
Xero hero: Philanthropy is a very private matter for Craig Winkler

2018-07-15 smh.com.au
Tech darling Xero will be holding its first shareholder meeting since ditching the Kiwi bourse, and company founder Rod Drury might be a tad nervous about facing re-election given the backlash on the other side of the ditch over the company's defection to the ASX.
BIG BGGNF

0
Xero hero: Philanthropy is a very private matter for Craig Winkler

2018-07-15 theage.com.au
Tech darling Xero will be holding its first shareholder meeting since ditching the Kiwi bourse, and company founder Rod Drury might be a tad nervous about facing re-election given the backlash on the other side of the ditch over the company's defection to the ASX.
BIG BGGNF

1
Nic Moore's Macquarie Group abandons YBR and Celebrity guru Mark Bouris

2018-05-22 theage.com.au
It’s not easy to tiptoe around when you’re a multi-billion dollar behemoth with nicknames like the millionaire’s factory, or the vampire kangaroo.
MQBKY BIG MCQEF MQG BGGNF

1
Nic Moore's Macquarie Group abandons YBR and Celebrity guru Mark Bouris

2018-05-22 smh.com.au
It’s not easy to tiptoe around when you’re a multi-billion dollar behemoth with nicknames like the millionaire’s factory, or the vampire kangaroo.
MQBKY BIG MCQEF MQG BGGNF

1
Nic Moore's Maquarie Group abandons YBR and Celebrity guru Mark Bouris

2018-05-22 theage.com.au
It’s not easy to tiptoe around when you’re a multi-billion dollar behemoth with nicknames like the millionaire’s factory, or the vampire kangaroo.
MQBKY BIG MCQEF MQG BGGNF

1
Nic Moore's Maquarie Group abandons YBR and Celebrity guru Mark Bouris

2018-05-22 smh.com.au
It’s not easy to tiptoe around when you’re a multi-billion dollar behemoth with nicknames like the millionaire’s factory, or the vampire kangaroo.
MQBKY BIG MCQEF MQG BGGNF

211
Tech Stocks Wanted: Australia’s ASX Exchange Aims to Add Startups - Bloomberg

2018-05-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TEAM JBK GS.PRICL GSC TFG GS.PRB GS.PRA BGGNF GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC AAPL BIG GJS GS.PRN GS.PRK

0
Three signs of the boom

2018-03-27 smh.com.au
Despite the weight of recent evidence, the economy and stock market are cyclical beasts. Yes, it’s been two and a half decades since the last recession, and the Australian Securities Exchange has doggedly climbed for over a decade, post global financial crisis, but these are the exceptions, not the rule.
BIG BGGNF

0
Crimes and misdemeanors catch up with Big Un boss Richard Evertz

2018-03-20 theage.com.au
Richard Evertz’s Big Un Ltd - the operator of Big Review TV - enthralled the sharemarket after convincing everyone it was successfully charging small businesses up to $12,000 to film a promotional video for them and post it on YouTube.
BIG BGGNF

0
Crimes and misdemeanors catch up with Big Un boss Richard Evertz

2018-03-20 smh.com.au
Richard Evertz’s Big Un Ltd - the operator of Big Review TV - enthralled the sharemarket after convincing everyone it was successfully charging small businesses up to $12,000 to film a promotional video for them and post it on YouTube.
BIG BGGNF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BIG / BIG UN LIMITED on message board site Silicon Investor.

Big Dogu0027s Boom Boom Room The Big Turnaround
Waiting for the big Kahuna Schlumberger - The biggest/baddest oil service company
Biglari Holdings, Inc. AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug
The World���s Biggest Wealth Fund Hits $1 Trillion MBRX under $3 announced big break through for Leukemia
The Naked Truth - Big Kahuna a Myth The bigots who are DonaldTrumpSupporers